Evogene Ltd.

Evogene Ltd. announced its Annual General Meeting of Shareholders to be held on September 4, 2026, where shareholders will vote on several key proposals. These include the re-election of directors, with a contested election between the Board-nominated Evogene Slate and a shareholder-nominated Pure Capital Slate, an increase in authorized share capital, and a framework for a reverse share split. The Board also highlighted significant operational transformations, including a reduction in headcount, decreased cash burn, and strategic portfolio optimization, while urging shareholders to support its proposed director slate.

Evogene Ltd. increased the maximum aggregate offering price of its at-the-market offering by $361,613 to $3,288,113. Concurrently, the company updated its risk factors to address an ongoing shareholder activism campaign. Activist shareholders are demanding an extraordinary general meeting to remove all current board members, excluding the CEO, and replace them with their own nominees, posing significant risks to the company's operations and stability.

Evogene Ltd. presented its proprietary generative AI engine, ChemPass AI, designed for the discovery and optimization of small molecules. The technology aims to revolutionize the pharmaceutical and ag-chemical industries by generating novel, highly potent compounds optimized across multiple parameters. The company emphasizes its ability to overcome limitations of traditional methods, such as confined chemical space and lack of simultaneous multi-parameter optimization, through its three-step process: PointHit, ActiveSearch, and LeadOp GPT. This AI-first approach is expected to increase the probability of success in developing new products.

Evogene Ltd. has entered into a Sales Agreement with A.G.P./Alliance Global Partners to conduct an "at the market offering." The company may offer and sell its ordinary shares for an aggregate offering price of up to $2,926,500. The Agent will receive a 3.0% commission on the gross proceeds from any sales.

Evogene reported Q1 2026 financial results with revenues of $0.3 million, a significant decrease from the prior year, and an increased net loss of $5.9 million. The company highlighted strategic advancements, including expanding its pharma division with three new collaborations and progressing its ChemPass AI™ platform. While the herbicide development project with Bayer was discontinued, non-core subsidiaries Lavie Bio and Biomica are winding down operations and distributing dividends.

Evogene Ltd. announced that its subsidiary, Ag Plenus Ltd., and Bayer Ag have mutually agreed to discontinue their herbicide development project. The decision was made because the target protein did not meet the required product criteria. Effective May 18, 2026, all assets previously licensed to Bayer under the collaboration, including the APTH1 protein target and associated active molecules, will revert to Ag Plenus.